# NCT06318871 (NCT06318871)

> Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06318871
- Phase: EARLY_PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Renal Carcinoma; Renal Cell Carcinoma; Urothelial Carcinoma; Chromophobe Renal Cell Carcinoma; Translocation Renal Cell Carcinoma
- Interventions: Cytokine Induced Memory-like Natural Killer (CIML NK) Cells; Interleukin-2 (IL-2)
- Enrollment: 5
- Primary outcome: Feasibility Failure Rate (FFR)

## Indexed commentary on NCT06318871 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct06318871